BioVendor Group Unveils Latest Innovations in Immunodiagnostics and Molecular Diagnostics
|
By LabMedica International staff writers Posted on 08 Feb 2024 |
BioVendor Group (Brno, Czech Republic) is participating in Medlab Middle East 2024 where it is unveiling the latest innovations in immunodiagnostics and molecular diagnostics. Visitors to the BioVendor booth at the show can explore its portfolio and meet experts from BioVendor LM, BioVendor MDx, TestLine, DiaSource, and ViennaLab to discuss how its advancements can benefit their work in the field of laboratory medicine.
BioVendor Group CLIA solution brings a fully automated walk-away platform, which significantly increases the efficiency of the laboratory workflow. It redefines the standards of fluency of diagnostic laboratories and provides reliable results. The KleeYa analyzer is also part of the booth and is being demonstrated to visitors by an application specialist. The KleeYa analyzer is an open platform system that handles tests from various providers and can combine a wide variety of assay designs. KleeYa provides a unique approach to the use of different bead-based chemiluminescence technologies, offering superior assay performance and providing ease of use with cost containment.
At the BioVendor booth, TestLine is presenting its latest innovations in laboratory diagnostics that are shaping the future of diagnostics. Visitors can explore the versatility of its Microblot-Array technology and its impact on the development of laboratory diagnostics worldwide. Microblot–Array is a new generation of unique, immunoblot arrays in a microtiter plate format. It is designed for efficient multiplex diagnostics, enabling the simultaneous detection of multiple markers which can save time and lower costs. The technology eliminates the limited capacity of traditional BLOT strips and opens the opportunity for high throughput testing. Processing can be performed automatically using open ELISA analyzers. The evaluation is performed by the Microblot–Array Reader and software (SW). Results can be exported in various formats and the system can be connected to LIS.
DiaSource ImmunoAssays is also sharing the same booth as BioVendor Group where it is presenting its latest diagnostic devices, recent innovations, and equipment in the fields of immunodiagnostics and molecular diagnostics. On display are the company’s RIA instruments, IMMUNOBLOT instruments, ELISA instruments, and CLIA instruments. Experts from BioVendor MDx are presenting its expanded fastGEN portfolio with user-friendly kits for the analysis of various genes. The latest addition is the fastGEN TP53 Cancer kit which is intended for the detection of mutations in exons 2-11 as well as in the two non-canonical exons between exons 9 and 10. Visitors to the booth can also learn more about the all-in-one solution fastGEN including bioinformatic analysis software GENOVESA.
Latest Medlab 2024 News
- Anbio Biotechnology Presents Point-Of-Care IVD Solutions
- 77 Elektronika Showcases Latest Developments in Urinalysis
- Sansure Presents Future of Pathogen Identification and Disease Diagnosis
- Spinreact Presents Latest Developments in IVD
- Alifax Demonstrates Automated Solutions to Improve Performance in Laboratory Settings
- YHLO Unveils New iBC 900 Automated Chemistry Analyzer
- Lifotronic Demonstrates Latest Medical Innovations in Disease Diagnostics
- Dymind Introduces New High-End Hematology Analyzer with Innovative Functions
- DIRUI Exhibits Latest Lab Automation Technologies and Devices
- Beckman Coulter Unveils DxC 500 AU Chemistry Analyzer
- Boule Presents Next Generation Hematology and Clinical Chemistry Systems
- bioMérieux Showcases Advanced Generation of VIDAS Immunoassay Solution
- BioPerfectus Highlights Diagnostic Solutions for HPV & Cervical Cancer Screening, STIs and Vector-Borne Diseases
- Mindray Showcases Range of Advanced Total IVD Solutions
- Medlab Middle East 2024 Provides a Peek into the Laboratory of the Future
Channels
Clinical Chemistry
view channel
Blood Test Detects More High-Risk Prostate Cancers Than PSA
Prostate cancer is one of the most common malignancies in men, and screening often struggles to distinguish indolent tumors from clinically significant disease. Prostate-specific antigen (PSA) testing... Read more
Rapid Blood Test Aids Diagnosis of Acute Ischemic Stroke
Rapid and accurate differentiation of stroke types remains a persistent challenge in emergency medicine, particularly because early imaging can miss ischemic events that require time-sensitive intervention.... Read moreMolecular Diagnostics
view channel
Genomic Test Guides Taxane-Based Chemotherapy Selection in Breast Cancer
Selecting adjuvant chemotherapy for hormone receptor–positive, HER2-negative (HR+/HER2−) breast cancer remains challenging because current genomic assays mainly estimate recurrence risk rather than predict... Read more
RNA Blood Test May Enable Earlier Alzheimer’s Disease Diagnosis
Alzheimer’s disease affects an estimated 55 million people worldwide and remains difficult to diagnose at an early stage. Diagnostic workups can be complicated by symptom overlap with other conditions,... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Lab-on-a-Chip Approach Advances Immune–Cancer Cell Interaction Analysis
Conventional cytotoxicity assays often average responses across thousands of cells, obscuring how individual immune cells engage and kill tumor cells. For immunotherapy evaluation, the precise sequence... Read more
Antibody Profiles Provide Clues to Long COVID Severity and Symptoms
Persistent symptoms after acute COVID-19 affect millions of people, causing fatigue, respiratory issues, and cognitive deficits that can be difficult to quantify with standard tests. Clinical teams lack... Read moreMicrobiology
view channel
Study Reveals Widespread Community Spread of Drug-Resistant Klebsiella
Multidrug-resistant Klebsiella pneumoniae is an escalating community health concern, driving recurrent urinary tract infections in older adults and complicating first-line antibiotic therapy.... Read more
Stronger Laboratory Services Support Timely Melioidosis Diagnosis Amid Global Spread
Melioidosis, a potentially fatal infection caused by Burkholderia pseudomallei, remains difficult to recognize because its symptoms can mimic tuberculosis and other illnesses. The disease is considered... Read more
Extracellular Vesicle Biomarker May Enable Noninvasive Monitoring of H. pylori
Helicobacter pylori infects an estimated 43.9% of the global population, affecting approximately 4.4 billion people worldwide. In many regions, including Africa, Eastern Europe, and Southeast Asia, prevalence... Read more
Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE
Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read morePathology
view channel
Study Highlights Biomarker Testing Delays in Lung Cancer Care
Timely biomarker results are critical to match lung cancer patients with targeted therapies or immunotherapies, yet many clinical pathways still delay testing after biopsy. Ordering responsibility, reimbursement... Read more
Stain-Free Imaging Platform Matches Standard Cancer Pathology
Histopathology underpins cancer diagnosis, but turnaround times and inter-laboratory variability can limit timely, consistent interpretation. Conventional staining relies on chemical dyes and multiple... Read more
New Companion Diagnostic Expands Precision Medicine in Prostate Cancer
Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more
Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer
Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Partnership Aims to Improve Transplant Monitoring Across Care Continuum
Allograft rejection and chronic graft dysfunction remain major challenges in solid organ transplantation, requiring careful immunologic matching and long-term surveillance. Fragmented pre- and post-transplant... Read more
QIAGEN Enhances QIAcuity Platform with Gene Expression and Multiplexing Tools
QIAGEN (Venlo, Netherlands) has introduced additions to its QIAcuity dPCR ecosystem that focus on gene expression, expanded assay content, and workflow standardization for life sciences and biopharma users.... Read more









